ArticleArthritis research & therapy2026
Global variation in the quality of care for rheumatoid arthritis and associated factors.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global inequities in biologic and targeted DMARD use in rheumatoid arthritis: cross-sectional data from the international COVAD-2 cohort.Rheumatology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAlthough the quality of care related to rheumatoid arthritis (RA) has improved, ensuring high-quality care globally remains a significant challenge. To address this issue, we have introduced a modified Quality of Care Index (QCI) to evaluate variations in RA care services worldwide and analyze the influencing factors.
methodsThe QCI was derived from a principal component analysis of global incidence, mortality, and prognostic indicators of RA. Joinpoint regression and linear mixed models were employed to analyze the temporal trends of the QCI and its influencing factors.
resultIn 2021, the global QCI for RA was 72.09. Among this, the QCI for males was 77.25, while for females it was 71.12. Based on Joinpoint regression, the AAPC of the global RA QCI from 1990 to 2021 was 0.30(0.29-0.31), with 0.22(0.20-0.23) for males and 0.29(0.28-0.30) for females. Based on the LMM model, it was found that age, gender, year, and SDI were all statistically significantly associated with QCI (p < 0.05). Specifically, positive correlations with QCI were observed in the following groups: under 14 years, 20-24 years, 40-54 years, 70-74 years, males, and high-SDI regions. Conversely, negative correlations with QCI were identified in the age groups 15-19 years, 25-39 years, 55-69 years, and 75 years and above.
conclusionDisparities in RA-related care exist across gender, age, and geographic regions. Further emphasis should be placed on improving care for female RA patients and those in low-SDI regions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.